PI 3-kinase C2β Antibody (16L9): sc-100407

PI 3-kinase C2β Antibody (16L9) is a mouse monoclonal IgG2a kappa light chain antibody that detects PI 3-kinase C2β in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-PI 3-kinase C2β antibody (16L9) is available in a non-conjugated form, allowing for versatile experimental use. PI 3-kinase C2β, also known as p110-β, is a crucial component of the phosphoinositide 3-kinase (PI 3-K) family, which plays a significant role in cellular signaling pathways that regulate cell growth and survival. PI 3-kinase C2β is composed of 1,070 amino acids and phosphorylates the 3′-OH position of inositol lipids, thereby influencing various cellular processes. PI 3-kinase C2β modulates the formation and stability of integrin adhesion bonds, specifically α2B (ITGA2B) and β3 (ITGB3), which are vital for platelet activation in response to shear forces. PI 3-kinase C2β interaction with these integrins underscores its importance in hemostasis and thrombosis, making PI 3-kinase C2β a key target for research in cardiovascular diseases and platelet function.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PI 3-kinase C2β Antibody (16L9) References:

1. Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase-related receptors.  |  Katada, T., et al. 1999. Chem Phys Lipids. 98: 79-86. PMID: 10358930
2. The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling.  |  Hooshmand-Rad, R., et al. 2000. J Cell Sci. 113 Pt 2: 207-14. PMID: 10633072
3. Gene encoding the catalytic subunit p110beta of human phosphatidylinositol 3-kinase: cloning, genomic structure, and screening for variants in patients with type 2 diabetes.  |  Kossila, M., et al. 2000. Diabetes. 49: 1740-3. PMID: 11016459
4. PI 3-kinase p110beta: a new target for antithrombotic therapy.  |  Jackson, SP., et al. 2005. Nat Med. 11: 507-14. PMID: 15834429
5. Class I PI3K in oncogenic cellular transformation.  |  Zhao, L. and Vogt, PK. 2008. Oncogene. 27: 5486-96. PMID: 18794883
6. Ablation of PI3K p110-α prevents high-fat diet-induced liver steatosis.  |  Chattopadhyay, M., et al. 2011. Diabetes. 60: 1483-92. PMID: 21464441
7. PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2.  |  Wahane, SD., et al. 2014. J Neurochem. 130: 255-67. PMID: 24645666
8. Role of protein kinase A and class II phosphatidylinositol 3-kinase C2β in the downregulation of KCa3.1 channel synthesis and membrane surface expression by lyso-globotriaosylceramide.  |  Choi, JY. and Park, S. 2016. Biochem Biophys Res Commun. 470: 907-12. PMID: 26820527
9. Direct association of p110 beta phosphatidylinositol 3-kinase with p85 is mediated by an N-terminal fragment of p110 beta.  |  Hu, P. and Schlessinger, J. 1994. Mol Cell Biol. 14: 2577-83. PMID: 8139559
10. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85.  |  Hu, P., et al. 1993. Mol Cell Biol. 13: 7677-88. PMID: 8246984
11. A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction.  |  Roche, S., et al. 1998. Mol Cell Biol. 18: 7119-29. PMID: 9819398
12. Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity.  |  Arcaro, A., et al. 1998. J Biol Chem. 273: 33082-90. PMID: 9830063

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-PI 3-kinase C2β Antibody (16L9) has 10 citations in a variety of scientific publications.

Primary antibodies like Anti-PI 3-kinase C2β Antibody (16L9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

PI 3-kinase C2β Antibody (16L9) Specifications

Alternate Product Name: PI3K C2 beta

Product Clone Name: 16L9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 1-111

Epitope Target: PI 3-kinase C2β

Epitope Species: human

Product Reactivity/Detection: PI 3-kinase C2β

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 50 µg IgG_2a kappa light chain in 0.5 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 10 citations in various scientific publications

Available Conjugates/Forms for PI 3-kinase C2β Antibody (16L9): N/A